RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address high unmet medical needs. We believe that we are well positioned to compete successfully using our RNAi technology platform for the development of novel therapeutics to improve patients’ lives. The Company is supported by a proven and experienced management team, an accomplished Scientific Advisory Board and an extensive intellectual property portfolio.
PROPRIETARY SELF-DELIVERING RNAi (sd-rxRNA®) TECHNOLOGY PLATFORM
Provided by Nasdaq.
Feb 12, 2018 at 2:15 PM ESTBIO CEO and Investor Conference
Jan 23, 2018 at 11:50 AM ESTTargeting Immune Checkpoints Using Self-Delivering RNAi (sd-rxRNA®) Technology
Jan 8, 2018 at 9:30 AM PSTBiotech Showcase Conference